INNOCARE announced that the BCL2 inhibitor ICP-248 (Mesutoclax), developed independently, combined with the BTK inhibitor obinutuzumab for the treatment of first-line chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), has received approval from the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) to conduct a registered Phase III clinical trial. The clinical research has already been initiated by the company. ICP-248 (Mesutoclax) is a novel oral high-selectivity BCL2 inhibitor that selectively inhibits the BCL2 protein, restoring apoptosis in tumor cells, thus inhibiting tumor growth and Diffusion. The fixed treatment regimen of ICP-248 (Mesutoclax) and obinutuzumab will provide deeper remission for first-line CLL/SLL patients and avoid the emergence of resistant mutations.